Flowers CR, Matasar MJ, Herrera AF, Hertzberg M, et al. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Haematologica 2023 Sep 28. doi: 10.3324/haematol.2023.283557.
PMID: 37767550